Phase 3 Type 2 Diabetes Trial, Recruiting NCT06589765 Sponsor: Shandong Suncadia Medicine Co., Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT06589765
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (inclusive)
  • You have been diagnosed with type 2 diabetes for at least 3 months before the screening visit
  • Your HbA1c (a measure of average blood sugar over recent months) was between 7.5% and 11.0% at your screening appointment
  • You have been making lifestyle changes (such as diet and exercise) and have been taking metformin at a dose of at least 1500 mg per day, consistently, for at least 8 weeks before screening

Who may not be able to join:

  • You have a known or suspected allergy to the trial drug or any of its ingredients
  • You have been diagnosed with, or are suspected of having, type 1 diabetes or another specific or secondary form of diabetes
  • You have had a serious diabetes-related emergency (such as diabetic ketoacidosis or a very high blood sugar crisis) within the 6 months before screening
  • You have certain serious diabetes-related complications, such as advanced eye disease, severe nerve pain, diabetic foot ulcers, or circulation problems in the legs that need urgent treatment
  • You are pregnant, breastfeeding, or planning to become pregnant during the trial; or you are a woman who could become pregnant or a man, and you are not using adequate contraception (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
27 September 2024
Est. completion
18 February 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from baseline in HbA1c at 32 weeks of treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov